Announcements Trials
Browse Landscape

Phase

Phase 1 13Phase 3 8Phase 1/2 3Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Melanoma 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × capivasertib × Clear all
NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT03742102 2026-04-24

BEGONIA

AstraZeneca

Phase 1/2 Active not recruiting
243 enrolled 13 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
435 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡